Fluocinolone acetonide (topical): Difference between revisions

Fluocinolone acetonide (topical)
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

← Older edit Newer edit →

VisualWikitext

Revision as of 18:02, 3 February 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Fluocinolone acetonide (topical) is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Fluocinolone Acetonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.

Dosage

Fluocinolone Acetonide Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation.

If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Fluocinolone acetonide (topical) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluocinolone acetonide (topical) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Fluocinolone acetonide (topical) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Fluocinolone acetonide (topical) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluocinolone acetonide (topical) in pediatric patients.

Contraindications

There is limited information regarding Fluocinolone acetonide (topical) Contraindications in the drug label.

Warnings

There is limited information regarding Fluocinolone acetonide (topical) Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Fluocinolone acetonide (topical) in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Fluocinolone acetonide (topical) in the drug label.

Drug Interactions

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Fluocinolone acetonide (topical) in women who are pregnant.
Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Fluocinolone acetonide (topical) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Fluocinolone acetonide (topical) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Fluocinolone acetonide (topical) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Fluocinolone acetonide (topical) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Fluocinolone acetonide (topical) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Fluocinolone acetonide (topical) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Fluocinolone acetonide (topical) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Fluocinolone acetonide (topical) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Fluocinolone acetonide (topical) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Fluocinolone acetonide (topical) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Fluocinolone acetonide (topical) in patients who are immunocompromised.

Administration and Monitoring

Administration

Topical

Monitoring

There is limited information regarding Monitoring of Fluocinolone acetonide (topical) in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Fluocinolone acetonide (topical) in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Fluocinolone acetonide (topical) in the drug label.

Pharmacology

There is limited information regarding Fluocinolone acetonide (topical) Pharmacology in the drug label.

Mechanism of Action

Structure

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Fluocinolone acetonide (topical) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Fluocinolone acetonide (topical) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Fluocinolone acetonide (topical) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Fluocinolone acetonide (topical) in the drug label.

How Supplied

Storage

There is limited information regarding Fluocinolone acetonide (topical) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Fluocinolone acetonide (topical) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Fluocinolone acetonide (topical) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Fluocinolone acetonide (topical) in the drug label.

Precautions with Alcohol

Alcohol-Fluocinolone acetonide (topical) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

FLUOCINOLONE ACETONIDE

Look-Alike Drug Names

A® — B®^[1]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Fluocinolone acetonide (topical)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Fluocinolone acetonide (topical)
 |Label Name=Fluocinolone acetonide (topical)11.png

}}

{{#subobject:

 |Label Page=Fluocinolone acetonide (topical)
 |Label Name=Fluocinolone acetonide (topical)11.png

}}

[www.ismp.org-1] "http://www.ismp.org". External link in |title= (help)

[1]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
 |authorTag={{KS}}
+|genericName=fluocinolone acetonide
 |aOrAn=a
-|hasBlackBoxWarning=Yes
 |adverseReactions=<!--Black Box Warning-->
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
@@ Line 12: / Line 12: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult===Indications==
+* Fluocinolone Acetonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.
-* Dosing Information
+==Dosage==
-:* Dosage
+* Fluocinolone Acetonide Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.
-=====Condition2=====
+* Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation.
-* Dosing Information
+* If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-:* Dosage
-=====Condition3=====
+|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-* Dosing Information
-:* Dosage
-=====Condition4=====
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-<!--Off-Label Use and Dosage (Adult)-->
-<!--Guideline-Supported Use (Adult)-->
-|offLabelAdultGuideSupport======Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-<!--Non–Guideline-Supported Use (Adult)-->
-|offLabelAdultNoGuideSupport======Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-<!--Pediatric Indications and Dosage-->
-<!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
+|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Developed by:
-* Class of Recommendation:
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Strength of Evidence:
-* Dosing Information
+|warnings=
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Non–Guideline-Supported Use (Pediatric)-->
-|offLabelPedNoGuideSupport======Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Contraindications-->
-|contraindications=* Condition1
-<!--Warnings-->
-|warnings=* Description
-====Precautions====
-* Description
-<!--Adverse Reactions-->
-<!--Clinical Trials Experience-->
 |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
-=====Cardiovascular=====
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
-<!--Postmarketing Experience-->
 |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
-=====Cardiovascular=====
+|drugInteractions=*
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
-<!--Drug Interactions-->
-|drugInteractions=* Drug
-:* Description
-<!--Use in Specific Populations-->
-|useInPregnancyFDA=* '''Pregnancy Category'''
 |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
@@ Line 264: / Line 65: @@
 <!--Administration and Monitoring-->
-|administration=* Oral
+|administration=* Topical
+|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Intravenous
-|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Description
-<!--IV Compatibility-->
 |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
-<!--Overdosage-->
-|overdose====Acute Overdose===
-====Signs and Symptoms====
+|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-* Description
-====Management====
-* Description
+|mechAction=*
-===Chronic Overdose===
-There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacology-->
-<!--Drug box 2-->
-|drugBox=<!--Mechanism of Action-->
-|mechAction=*
-<!--Structure-->
 |structure=*
-: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
-<!--Pharmacodynamics-->
 |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacokinetics-->
 |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
-<!--Nonclinical Toxicology-->
 |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
-<!--Clinical Studies-->
 |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
-<!--How Supplied-->
 |howSupplied=*
-|packLabel=<!--Patient Counseling Information-->
 |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
-<!--Precautions with Alcohol-->
 |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
-<!--Brand Names-->
-|brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>
-<!--Look-Alike Drug Names-->
+|brandNames=* FLUOCINOLONE ACETONIDE
 |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>

Fluocinolone acetonide (topical): Difference between revisions

Revision as of 18:02, 3 February 2015

Disclaimer

Overview

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Non–Guideline-Supported Use

Contraindications

Warnings

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Drug Interactions

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatic Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Administration and Monitoring

Administration

Monitoring

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Nonclinical Toxicology

Clinical Studies

How Supplied

Storage

Images

Drug Images

Package and Label Display Panel

Patient Counseling Information

Precautions with Alcohol

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

Navigation menu

Search